HTA of the Innovative Medicines in Germany

ISBN-13: 9786202069885 / Angielski / Miękka / 2017 / 88 str.

Mohamed Shanshan

Opis

The Market Access of the innovative medicines, is monitored by both Regulators and Payers. To assess the new drugs; if they deliver a fair value for money. The remarkable recent discrepancies between both parties' requirements during the market entry process, represent a financial threat on the Pharmaceutical industry. The evolving restrictions would alter the industry motive to invest in Research and Development. Consequently, patients will not receive the appropriate medicines to win their battles against the developed ailments which may then contribute to a public health alarm.

O autorze

I am a pharmaceutical professional with 10 years' experience in international pharma giants. I have worked for Pfizer, Johnson & Johnson, Boehringer Ingelheim and Sanofi. Until recently, I have executed a MSc degree in International Pharmacoeconomics and Health Economics offered by Cardiff University, United Kingdom.